ROYALTY PHARMA PLC- CL A (RPRX)

GB00BMVP7Y09 - Common Stock

31.24  +0.01 (+0.03%)

News Image
a day ago - Chartmill

Promising Signs: ROYALTY PHARMA PLC- CL A Setting the Stage for a Breakout.

ROYALTY PHARMA PLC- CL A is showing promising signs of setting up for a breakout.

News Image
6 days ago - The Motley Fool

Wall Street Thinks These 3 Stocks Are Hidden Gems That Could Soar 43% to 59% Over the Next 12 Months

Analysts are quite bullish about these beaten-down stocks.

News Image
7 days ago - Seeking Alpha

Royalty Pharma reports Q4 results (NASDAQ:RPRX)

Royalty Pharma press release (RPRX): Q4 net income of $718M Revenue of $596M (+5.3% Y/Y) misses by $78.54M. More on Royalty Pharma Royalty Pharma: One Of The Be

News Image
7 days ago - Royalty Pharma plc

Royalty Pharma Reports Q4 and Full Year 2023 Results

Portfolio Receipts of $736 million in Q4 2023 and $3,049 million for FY 2023Net cash provided by operating activities of $773 million in Q4 2023 and $2,988...

News Image
14 days ago - InvestorPlace

3 Biotech Stocks to Buy for the Next Bull Run: February 2024

These are the biotech stocks to buy that you must have on your watchlist for the coming bull run. It could get started as soon as this month.

News Image
14 days ago - Chartmill

NASDAQ:RPRX is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.

ROYALTY PHARMA PLC- CL A (NASDAQ:RPRX) is an undervalued gem with solid fundamentals.

News Image
23 days ago - Royalty Pharma plc

Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024

NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2023...

News Image
a month ago - Seeking Alpha

Royalty Pharma raises dividend by 5% (NASDAQ:RPRX)

Royalty Pharma (RPRX) announced a 5% increase in its quarterly dividend to $0.21/share.

News Image
a month ago - Royalty Pharma plc

Royalty Pharma Announces Dividend Increase

News Image
a month ago - Royalty Pharma plc

Royalty Pharma Announces Dividend Increase

NEW YORK, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the...

News Image
3 months ago - Royalty Pharma plc

Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference

NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at...

News Image
3 months ago - Royalty Pharma plc

Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program

Royalty Pharma to provide R&D funding support of up to $125 million for the development of olanzapine LAI (TEV-‘749), a long-acting subcutaneous...

News Image
4 months ago - Seeking Alpha

Royalty Pharma reports Q3 results (NASDAQ:RPRX)

Royalty Pharma press release (RPRX): Q3 net income of $122M Revenue of $536M (-6.5% Y/Y) misses by $82.49M. Announced transactions of up to $3.8 billion year-to

News Image
4 months ago - Royalty Pharma plc

Royalty Pharma Reports Third Quarter 2023 Results

News Image
4 months ago - Royalty Pharma plc

Royalty Pharma Reports Third Quarter 2023 Results

Net cash provided by operating activities (GAAP) of $574 million and Adjusted Cash Receipts(1) (non-GAAP) of $637 millionAnnounced transactions of up to...

News Image
4 months ago - The Motley Fool

Why PTC Therapeutics Soared 15% Higher Today

The company scored a $1 billion upfront payment for expanding a commercial partnership.

News Image
4 months ago - Seeking Alpha

Royalty Pharma to buy up to $1.5B of PTC Therapeutics’ royalty on Evrysdi (NASDAQ:RPRX)

Royalty Pharma to buy additional royalties on Roche's Evrysdi for $1 billion upfront, increasing ownership from 43% to 81%.

News Image
4 months ago - Royalty Pharma plc

Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics’ Royalty on Evrysdi

Royalty Pharma purchases a portion of royalties on Roche’s Evrysdi for $1.0 billion upfrontPTC Therapeutics has option to sell rest of royalty for up to...

News Image
4 months ago - Royalty Pharma plc

Royalty Pharma Declares Fourth Quarter 2023 Dividend

NEW YORK, Oct. 16, 2023 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the...

News Image
4 months ago - Royalty Pharma plc

Royalty Pharma To Announce Third Quarter 2023 Financial Results On November 8, 2023

NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2023 financial...

News Image
5 months ago - Seeking Alpha

Royalty Pharma appoints chief technology officer (NASDAQ:RPRX)

Biopharmaceutical company Royalty Pharma appoints Eric Schneider as their new chief technology officer, joining from Verisk, a data-driven analytic insights provider.